Roanoke Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $3.69M | Buy |
60,465
+2,563
| +4% | +$149K | 1.26% | 34 |
|
|
2024
Q4 | $3.27M | Buy |
57,902
+1,883
| +3% | +$105K | 1.05% | 37 |
|
|
2024
Q3 | $2.9M | Sell |
56,019
-2,445
| -4% | -$115K | 0.91% | 38 |
|
|
2024
Q2 | $2.43M | Sell |
58,464
-775
| -1% | -$34.7K | 0.8% | 39 |
|
|
2024
Q1 | $3.21M | Sell |
59,239
-145
| -0.2% | -$7.39K | 1.05% | 37 |
|
|
2023
Q4 | $3.05M | Sell |
59,384
-17
| -0% | -$892 | 1.13% | 36 |
|
|
2023
Q3 | $3.45M | Sell |
59,401
-183
| -0.3% | -$11.2K | 1.41% | 30 |
|
|
2023
Q2 | $3.81M | Buy |
59,584
+6
| +0% | +$402 | 1.51% | 23 |
|
|
2023
Q1 | $4.13M | Buy |
59,578
+1
| +0% | +$71 | 1.76% | 19 |
|
|
2022
Q4 | $4.29M | Sell |
59,577
-2,960
| -5% | -$223K | 1.95% | 13 |
|
|
2022
Q3 | $4.45M | Buy |
62,537
+5
| +0% | +$363 | 2.12% | 11 |
|
|
2022
Q2 | $4.82M | Buy |
62,532
+10,535
| +20% | +$802K | 2.16% | 12 |
|
|
2022
Q1 | $3.8M | Sell |
51,997
-2,279
| -4% | -$153K | 1.41% | 28 |
|
|
2021
Q4 | $3.38M | Buy |
54,276
+2,376
| +5% | +$139K | 1.12% | 31 |
|
|
2021
Q3 | $3.07M | Buy |
51,900
+15
| +0% | +$988 | 1.09% | 35 |
|
|
2021
Q2 | $3.47M | Buy |
51,885
+7,615
| +17% | +$497K | 1.2% | 30 |
|
|
2021
Q1 | $2.79M | Buy |
44,270
+1,365
| +3% | +$84.9K | 1.21% | 27 |
|
|
2020
Q4 | $2.66M | Buy |
42,905
+320
| +0.8% | +$19.7K | 1.26% | 26 |
|
|
2020
Q3 | $2.57M | Buy |
42,585
+320
| +0.8% | +$19.3K | 1.4% | 21 |
|
|
2020
Q2 | $2.48M | Sell |
42,265
-2,421
| -5% | -$145K | 1.44% | 23 |
|
|
2020
Q1 | $2.49M | Sell |
44,686
-235
| -0.5% | -$14.4K | 1.68% | 23 |
|
|
2019
Q4 | $2.88M | Sell |
44,921
-7,099
| -14% | -$407K | 1.44% | 25 |
|
|
2019
Q3 | $2.64M | Sell |
52,020
-1,070
| -2% | -$50.3K | 1.23% | 28 |
|
|
2019
Q2 | $2.41M | Sell |
53,090
-230
| -0.4% | -$10.7K | 1.09% | 31 |
|
|
2019
Q1 | $2.54M | Hold |
53,320
| – | – | 1.19% | 29 |
|
|
2018
Q4 | $2.77M | Sell |
53,320
-695
| -1% | -$37.3K | 1.47% | 22 |
|
|
2018
Q3 | $3.35M | Sell |
54,015
-20
| -0% | -$1.19K | 1.51% | 21 |
|
|
2018
Q2 | $2.99M | Buy |
54,035
+2,285
| +4% | +$123K | 1.44% | 22 |
|
|
2018
Q1 | $3.27M | Sell |
51,750
-1,350
| -3% | -$86.8K | 1.58% | 18 |
|
|
2017
Q4 | $3.25M | Sell |
53,100
-8,325
| -14% | -$521K | 1.56% | 21 |
|
|
2017
Q3 | $3.92M | Sell |
61,425
-4,960
| -7% | -$290K | 1.84% | 17 |
|
|
2017
Q2 | $3.7M | Buy |
66,385
+10,140
| +18% | +$552K | 1.75% | 17 |
|
|
2017
Q1 | $3.06M | Sell |
56,245
-11,095
| -16% | -$609K | 1.45% | 28 |
|
|
2016
Q4 | $3.94M | Sell |
67,340
-2,150
| -3% | -$118K | 1.79% | 18 |
|
|
2016
Q3 | $3.75M | Buy |
69,490
+485
| +0.7% | +$31.2K | 1.69% | 22 |
|
|
2016
Q2 | $5.08M | Sell |
69,005
-274
| -0.4% | -$19.4K | 2.35% | 10 |
|
|
2016
Q1 | $4.43M | Sell |
69,279
-2,575
| -4% | -$162K | 2.05% | 16 |
|
|
2015
Q4 | $4.94M | Sell |
71,854
-8,910
| -11% | -$589K | 2.11% | 13 |
|
|
2015
Q3 | $4.78M | Hold |
80,764
| – | – | 1.76% | 20 |
|
|
2015
Q2 | $5.37M | Buy |
80,764
+1,425
| +2% | +$93.9K | 1.73% | 19 |
|
|
2015
Q1 | $5.12M | Sell |
79,339
-164
| -0.2% | -$10.3K | 1.68% | 23 |
|
|
2014
Q4 | $4.69M | Buy |
79,503
+8,375
| +12% | +$472K | 1.61% | 24 |
|
|
2014
Q3 | $3.64M | Sell |
71,128
-5,345
| -7% | -$267K | 1.49% | 30 |
|
|
2014
Q2 | $3.71M | Buy |
76,473
+6,780
| +10% | +$334K | 1.42% | 30 |
|
|
2014
Q1 | $3.62M | Buy |
69,693
+2,025
| +3% | +$108K | 1.6% | 27 |
|
|
2013
Q4 | $3.6M | Hold |
67,668
| – | – | 1.65% | 22 |
|
|
2013
Q3 | $3.51M | Buy |
+67,668
| New | +$2.97M | 1.7% | 23 |
|
Other funds holding BMY
Roanoke Asset Management's BMY Position: Q1 2025 in Review
Roanoke Asset Management increased its Bristol-Myers Squibb (BMY) stake by 4.4% in Q1 2025, buying an estimated $149K and bringing the position to 60,465 shares worth $3.69M. The position accounts for 1.26% of the portfolio, ranked #34.
Roanoke Asset Management first reported a position in BMY in Q3 2013 and has held it in 47 quarters since. The position peaked at $5.37M in Q2 2015. 2,477 funds tracked by Wall St. Rank hold BMY as of Q1 2025.
- Roanoke Asset Management held 60,465 shares of Bristol-Myers Squibb worth $3.69M as of Q1 2025.
- Roanoke Asset Management bought 2,563 Bristol-Myers Squibb shares in Q1 2025, an estimated $149K.
- Bristol-Myers Squibb made up 1.26% of Roanoke Asset Management's portfolio in Q1 2025, its #34 holding.
- Roanoke Asset Management first reported a position in Bristol-Myers Squibb in Q3 2013 and has held it in 47 quarters since.
- Roanoke Asset Management's Bristol-Myers Squibb position peaked at $5.37M in Q2 2015.
- 2,477 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2025.
Based on Roanoke Asset Management's 13F filing for Q1 2025, filed 13 May 2025.